Johnson & Johnson's Sudafed is one of the products containing decongestant phenylephrine. Photo: JB Reed/Bloomberg News Clogged Up: Lawsuits Are Flying Against Johnson & Johnson Over Decongestant
On Sept. 12, 2023, the FDA issued a report on phenylephrine, saying that there were no safety issues found with its use as a decongestant but there were also no benefits, the suit said.
January 29, 2024 at 05:57 PM
3 minute read
Securities Litigation
The original version of this story was published on New Jersey Law Journal
Securities fraud suits are multiplying over Johnson & Johnson's alleged failure to disclose questions about the effectiveness of its decongestant products when it conducted an initial public offering for spinoff division Kenvue.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Law Firms Mentioned
Trending Stories
- 1First Lawsuit Filed Alleging Contraceptive Depo-Provera Caused Brain Tumor
- 2BD Settles Thousands of Bard Hernia Mesh Lawsuits
- 3The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 4The Growing Tension—And Opportunity—in Big Law Nonequity Tiers
- 5The 'Biden Effect' on Senior Attorneys: Should I Stay or Should I Go?
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
